Regeneron defends US antitrust claims against Amgen
MLex Summary: Regeneron filed an opposition to Amgen’s motion to dismiss claims that it illegally kept Regeneron’s cholesterol-reducing drug Praluent off-market to block competition to Amgen’s own drug Repatha.See document below. ...To view the full article, register now.
Already a subscriber? Click here to view full article